100 related articles for article (PubMed ID: 35612832)
1. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarcinoma.
Shoucair S; Chen J; Martinson JR; Habib JR; Kinny-Köster B; Pu N; van Oosten AF; Javed AA; Shin EJ; Ali SZ; Lafaro KJ; Wolfgang CL; He J; Yu J
JAMA Surg; 2022 Jul; 157(7):e221362. PubMed ID: 35612832
[TBL] [Abstract][Full Text] [Related]
2. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer.
Cui M; Shoucair S; Liao Q; Qiu X; Kinny-Köster B; Habib JR; Ghabi EM; Wang J; Shin EJ; Leng SX; Ali SZ; Thompson ED; Zimmerman JW; Shubert CR; Lafaro KJ; Burkhart RA; Burns WR; Zheng L; He J; Zhao Y; Wolfgang CL; Yu J
Int J Surg; 2023 Feb; 109(2):99-106. PubMed ID: 36799816
[TBL] [Abstract][Full Text] [Related]
3. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
[TBL] [Abstract][Full Text] [Related]
5. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.
Zhu L; Shen S; Wang H; Zhang G; Yin X; Shi X; Gao S; Han J; Ren Y; Wang J; Jiang H; Guo S; Jin G
BMC Cancer; 2023 Aug; 23(1):790. PubMed ID: 37612635
[TBL] [Abstract][Full Text] [Related]
6. Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma.
Akumuo RC; Reddy SP; Westwood C; Devarajan K; Barrak D; Reddy SS; Villano AM
J Gastrointest Surg; 2024 May; 28(5):605-610. PubMed ID: 38704197
[TBL] [Abstract][Full Text] [Related]
7. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples.
Redegalli M; Grassini G; Magliacane G; Pecciarini L; Schiavo Lena M; Smart CE; Johnston RL; Waddell N; Maestro R; Macchini M; Orsi G; Petrone MC; Rossi G; Balzano G; Falconi M; Arcidiacono PG; Reni M; Doglioni C; Cangi MG
Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2825-2833. PubMed ID: 36280101
[TBL] [Abstract][Full Text] [Related]
8. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma.
Panni RZ; Gonzalez I; Hartley CP; Williams GA; Liu J; Hawkins WG; Chatterjee D
Am J Surg Pathol; 2018 Nov; 42(11):1480-1487. PubMed ID: 30179901
[TBL] [Abstract][Full Text] [Related]
9. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?
Donisi G; Nappo G; Pacilli M; Capretti GL; Spaggiari P; Sollai M; Bozzarelli S; Zerbi A
Updates Surg; 2023 Sep; 75(6):1497-1508. PubMed ID: 37578734
[TBL] [Abstract][Full Text] [Related]
10. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer.
Murthy P; Zenati MS; AlMasri SS; DeSilva A; Singhi AD; Paniccia A; Lee KK; Simmons RL; Bahary N; Lotze MT; Zureikat AH
J Natl Compr Canc Netw; 2023 Dec; 22(1D):e237070. PubMed ID: 38150819
[TBL] [Abstract][Full Text] [Related]
11. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic Ductal Adenocarcinoma.
Zhou L; Lu J; Liang ZY; Zhou WX; Wang YZ; Jiang BL; You L; Guo JC
Pancreas; 2021 Sep; 50(8):1195-1201. PubMed ID: 34714284
[TBL] [Abstract][Full Text] [Related]
12. Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma.
Chopra A; Zamora R; Vodovotz Y; Hodges JC; Barclay D; Brand R; Simmons RL; Lee KK; Paniccia A; Murthy P; Lotze MT; Boone BA; Zureikat AH
J Immunother; 2021 Jun; 44(5):185-192. PubMed ID: 33935273
[TBL] [Abstract][Full Text] [Related]
13. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis.
Davis CH; Augustinus S; de Graaf N; Wellner UF; Johansen K; Andersson B; Beane JD; Björnsson B; Busch OR; Gleeson EM; van Santvoort HC; Tingstedt B; Williamsson C; Keck T; Besselink MG; Koerkamp BG; Pitt HA;
J Am Coll Surg; 2024 Apr; 238(4):613-621. PubMed ID: 38224148
[TBL] [Abstract][Full Text] [Related]
14. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first.
Tong YT; Wang H; Wei D; Prakash LR; Kim M; Tzeng CD; Lee JE; Rashid A; Koay EJ; Wolff RA; Maitra A; Katz MH; Wang H
Pancreatology; 2021 Oct; 21(7):1378-1385. PubMed ID: 34429247
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma.
Nishiwada S; Cui Y; Sho M; Jun E; Akahori T; Nakamura K; Sonohara F; Yamada S; Fujii T; Han IW; Tsai S; Kodera Y; Park JO; Von Hoff D; Kim SC; Li W; Goel A
Ann Surg; 2022 Dec; 276(6):e876-e885. PubMed ID: 34132691
[TBL] [Abstract][Full Text] [Related]
16. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer.
Liu H; Zenati MS; Rieser CJ; Al-Abbas A; Lee KK; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2020 Oct; 27(10):3950-3960. PubMed ID: 32318949
[TBL] [Abstract][Full Text] [Related]
17. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society.
Wang H; Chetty R; Hosseini M; Allende DS; Esposito I; Matsuda Y; Deshpande V; Shi J; Dhall D; Jang KT; Kim GE; Luchini C; Graham RP; Reid MD; Basturk O; Hruban RH; Krasinskas A; Klimstra DS; Adsay V;
Am J Surg Pathol; 2022 Jun; 46(6):754-764. PubMed ID: 34889852
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
Miyahara S; Takahashi H; Akita H; Sasaki K; Mukai Y; Iwagami Y; Hasegawa S; Yamada D; Tomimaru Y; Noda T; Wada H; Kobayashi S; Doki Y; Eguchi H
Ann Surg Oncol; 2024 May; 31(5):2932-2942. PubMed ID: 38368291
[TBL] [Abstract][Full Text] [Related]
19. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach?
Puleo A; Malla M; Boone BA
Pancreas; 2022 Oct; 51(9):1083-1091. PubMed ID: 37078929
[TBL] [Abstract][Full Text] [Related]
20. Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study.
Park Y; Han YB; Kim J; Kang M; Lee B; Ahn ES; Han S; Kim H; Na HY; Han HS; Yoon YS
Pancreatology; 2024 Mar; ():. PubMed ID: 38556428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
